0000885590-14-000015.txt : 20140128 0000885590-14-000015.hdr.sgml : 20140128 20140128170011 ACCESSION NUMBER: 0000885590-14-000015 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140124 FILED AS OF DATE: 20140128 DATE AS OF CHANGE: 20140128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mirovsky Pavel CENTRAL INDEX KEY: 0001577638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 14553664 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST CITY: LAVAL STATE: A8 ZIP: H7L 4A8 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2014-01-24 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001577638 Mirovsky Pavel 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 President of Valeant Europe Common Stock, no par value 2014-01-24 4 M 0 10000 0 A 10000 D Restricted Share Units 2014-01-24 4 M 0 10000 0 D Common Stock 10000 10000 D This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% on May 15, 2015 and 25% on August 15, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value. by: Nicholas Zanoni for Pavel Mirovsky 2014-01-28